American International Group Inc. Increases Holdings in Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

American International Group Inc. boosted its holdings in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 6.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 119,921 shares of the company’s stock after purchasing an additional 7,431 shares during the period. American International Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $2,049,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Wetherby Asset Management Inc. increased its stake in shares of Teva Pharmaceutical Industries by 27.5% during the 1st quarter. Wetherby Asset Management Inc. now owns 13,265 shares of the company’s stock worth $227,000 after purchasing an additional 2,857 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Teva Pharmaceutical Industries by 1.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 198,178 shares of the company’s stock worth $3,755,000 after purchasing an additional 3,100 shares during the last quarter. WealthTrust Axiom LLC increased its stake in shares of Teva Pharmaceutical Industries by 29.9% during the 4th quarter. WealthTrust Axiom LLC now owns 14,948 shares of the company’s stock worth $283,000 after purchasing an additional 3,440 shares during the last quarter. Stephens Inc. AR increased its stake in shares of Teva Pharmaceutical Industries by 13.5% during the 4th quarter. Stephens Inc. AR now owns 36,813 shares of the company’s stock worth $698,000 after purchasing an additional 4,381 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in shares of Teva Pharmaceutical Industries by 21.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 28,789 shares of the company’s stock worth $546,000 after purchasing an additional 5,163 shares during the last quarter. 64.99% of the stock is owned by institutional investors and hedge funds.

In related news, Director Roberto Mignone acquired 750,000 shares of the stock in a transaction on Thursday, May 10th. The stock was purchased at an average price of $19.24 per share, for a total transaction of $14,430,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Insiders sold a total of 3,098 shares of company stock valued at $55,405 in the last 90 days. Corporate insiders own 0.43% of the company’s stock.

Shares of Teva Pharmaceutical Industries traded down $0.55, reaching $23.78, during mid-day trading on Thursday, Marketbeat reports. 12,433,856 shares of the stock were exchanged, compared to its average volume of 14,300,264. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 1.80. The stock has a market capitalization of $23.58 billion, a P/E ratio of 6.05, a price-to-earnings-growth ratio of 1.53 and a beta of 0.72. Teva Pharmaceutical Industries Ltd has a fifty-two week low of $10.85 and a fifty-two week high of $33.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Thursday, May 3rd. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.28. The firm had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.80 billion. Teva Pharmaceutical Industries had a negative net margin of 72.36% and a positive return on equity of 18.59%. The company’s quarterly revenue was down 10.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.06 EPS. equities analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.53 earnings per share for the current year.

Several brokerages have recently commented on TEVA. Citigroup set a $25.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research note on Thursday, May 31st. Barclays set a $20.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Thursday, May 24th. Cantor Fitzgerald set a $18.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Thursday, May 17th. ValuEngine upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Thursday, February 15th. Finally, Credit Suisse Group set a $23.00 target price on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Monday, May 14th. Ten research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $19.90.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Ruptured Biceps Tendon Ends Miguel Cabrera’s Season
Ruptured Biceps Tendon Ends Miguel Cabrera’s Season
Dodgers Getting Big Unexpected Lift from Three Players
Dodgers Getting Big Unexpected Lift from Three Players
What does legal betting mean for the baseball industry?
What does legal betting mean for the baseball industry?
Dodgers Use Nine Pitchers in Nine-Inning Game
Dodgers Use Nine Pitchers in Nine-Inning Game
Max Scherzer Throws Second Career Immaculate Inning
Max Scherzer Throws Second Career Immaculate Inning
Phillies Swept and Jake Arrieta Upset
Phillies Swept and Jake Arrieta Upset


Leave a Reply

 
© 2006-2018 BBNS.